Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain

ACS Medicinal Chemistry Letters

Volumn 6, Issue 6, 2015, Pages 650-654

  Bagal, Sharan K ^a   Bungay, Peter J ^a   Denton, Stephen M ^a   Gibson, Karl R ^a   Glossop, Melanie S ^a   Hay, Tanya L ^a   Kemp, Mark I ^a   Lane, Charlotte A L ^a   Lewis, Mark L ^a   Maw, Graham N ^a   Million, William A ^a   Payne, C Elizabeth ^a   Poinsard, Cedric ^a   Rawson, David J ^a   Stammen, Blanda L ^a   Stevens, Edward B ^a   Thompson, Lisa R ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Nav1.8; SCN10A; sodium channel drugs; TTX R; Voltage gated sodium channels

Indexed keywords

ANALGESIC AGENT; SODIUM CHANNEL NAV1.8; SODIUM CHANNEL NAV1.8 MODULATOR; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOAVAILABILITY; CONTROLLED STUDY; DEACETYLATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SOLUBILITY; HUMAN; HUMAN CELL; HYDROLYSIS; IC50; INFLAMMATORY PAIN; INTRINSIC CLEARANCE; LIPOPHILICITY; LIVER MICROSOME; METABOLITE; NEUROPATHIC PAIN; NONHUMAN; PH; PRIORITY JOURNAL; RAT; SOMATOSENSORY SYSTEM;

EID: 84935841733     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.5b00059     Document Type: Article

References (23)

1. Lampert, A.; Eberhardt, M.; Waxman, Stephen G. Altered sodium channel gating as molecular basis for pain: contribution of activation, inactivation, and resurgent currents Handb. Exp. Pharmacol. 2014, 221, 91 - 110
2. Dib-Hajj, S. D.; Cummins, T. R.; Black, J. A.; Waxman, S. G. Sodium channels in normal and pathological pain Annu. Rev. Neurosci. 2010, 33, 325 - 347
3. Amaya, F.; Decosterd, I.; Samad, T. A.; Plumpton, C.; Tate, S.; Mannion, R. J.; Costigan, M.; Woolf, C. J. Diversity of expression of the sensory neuron-specific TTX-resistant voltage-gated sodium ion channels SNS and SNS2 Mol. Cell. Neurosci. 2000, 15, 331 - 342
4. Shields, S. D.; Ahn, H.-S.; Yang, Y.; Han, C.; Seal, R. P.; Wood, J. N.; Waxman, S. G.; Dib-Hajj, S. D. Nav1.8 expression is not restricted to nociceptors in mouse peripheral nervous system Pain 2012, 153, 2017 - 2030
5. England, S.; Bevan, S.; Docherty, R. J. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurons via the cyclic AMP-protein kinase A cascade J. Physiol. 1996, 495, 429 - 440
6. Dib-Hajj, S. D.; Fjell, J.; Cummins, T. R.; Zheng, Z.; Fried, K.; LaMotte, R.; Black, J. A.; Waxman, S. G. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain Pain 1999, 83, 591 - 600
7. Akopian, A. N.; Souslova, V.; England, S.; Okuse, K.; Ogata, N.; Ure, J.; Smith, A.; Kerr, B. J.; McMahon, S. B.; Boyce, S.; Hill, R.; Stanfa, L. C.; Dickenson, A. H.; Wood, J. N. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways Nat. Neurosci. 1999, 2, 541 - 548
8. Kerr, B. J.; Souslova, V.; McMahon, S. B.; Wood, J. N. A role for the TTX-resistant sodium channel Nav 1.8 in NGF-induced hyperalgesia, but not neuropathic pain NeuroReport 2001, 12, 3077 - 3080
9. Minett, M. S.; Falk, S.; Santana-Varela, S.; Bogdanov, Y. D.; Nassar, M. A.; Heegaard, A.-M.; Wood, J. N. Pain without nociceptors? Nav1.7-independent pain mechanisms Cell Rep. 2014, 6, 301 - 312
10. Nassar, M. A.; Levato, A.; Stirling, L. C.; Wood, J. N. Neuropathic pain develops normally in mice lacking both Nav1.7 and Nav1.8 Mol. Pain 2005, 1, 24
11. Faber, C. G.; Lauria, G.; Merkies, I. S. J.; Cheng, X.; Han, C.; Ahn, H.-S.; Persson, A.-K.; Hoeijmakers, J. G. J.; Gerrits, M. M.; Pierro, T.; Lombardi, R.; Kapetis, D.; Dib-Hajj, S. D.; Waxman, S. G. Gain-of-function Nav1.8 mutations in painful neuropathy Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 19444 - 19449
12. Jarvis, M. F.; Honore, P.; Shieh, C.-C.; Chapman, M.; Joshi, S.; Zhang, X.-F.; Kort, M.; Carroll, W.; Marron, B.; Atkinson, R.; Thomas, J.; Liu, D.; Krambis, M.; Liu, Y.; McGaraughty, S.; Chu, K.; Roeloffs, R.; Zhong, C.; Mikusa, J. P.; Hernandez, G.; Gauvin, D.; Wade, C.; Zhu, C.; Pai, M.; Scanio, M.; Shi, L.; Drizin, I.; Gregg, R.; Matulenko, M.; Hakeem, A.; Gross, M.; Johnson, M.; Marsh, K.; Wagoner, P. K.; Sullivan, J. P.; Faltynek, C. R.; Krafte, D. S. A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 8520 - 8525
13. Caldwell, G. W.; Masucci, J. A.; Yan, Z.; Hageman, W. Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur. J. Drug Metab. Pharmacokinet. 2004, 29, 133 - 143
14. Payne, C. E.; Brown, A. R.; Theile, J. W.; Mahoney, J. H.; Loucif, A. J. C.; Alexandrou, A. J.; Fuller, M. D.; Antonio, B. M.; Gerlach, A. C.; Prime, R. L.; Stockbridge, G.; Kirkup, A. J.; Bagal, S. K.; Bannon, A. W.; England, S.; Chapman, M. L.; Roeloffs, R.; Bungay, P.; Anand, U.; Anand, P.; Kemp, M.; Butt, R. P.; Stevens, E. B. A novel oral NaV 1.8 blocker PF-01247324 attenuates nociception and neuronal excitability. Br. J. Pharmacol. 2015, 172 (10), 2654 - 2670; DOI: 10.1111/bph.13092.
15. Bagal, S. K.; Brown, A. D.; Cox, P. J.; Omoto, K.; Owen, R. M.; Pryde, D. C.; Sidders, B.; Skerratt, S. E.; Stevens, E. B.; Storer, R. I.; Swain, N. A. Ion channels as therapeutic targets: a drug discovery perspective J. Med. Chem. 2013, 56 (3) 593 - 624
16. hNav1.8 data generated in VSP-FRET hNav1.8 in HEK293 cells with at least three tests on three different assay runs. TTX-S data generated in VSP-FRET in SHSY5Y neuroblastoma cell line expressing hNav1.2, hNav1.3, and hNav1.7.
17. Freeman-Cook, K. D.; Hoffman, R. L.; Johnson, T. W. Lipophilic efficiency: the most important efficiency metric in medicinal chemistry Future Med. Chem. 2013, 5 (2) 113 - 115
18. Lane, C. A. L.; Maw, G. N.; Rawson, D. J.; Thompson, L. R. Pyridine derivatives. WO2006011050, 2006.
19. Bagal, S. K.; Gibson, K. R.; Kemp, M. I.; Poinsard, C.; Stammen, B. L.; Denton, S. M.; Glossop, M. S. Pyridine derivatives. WO2008135826, 2008.
20. Kemp, M. I. 2,6-Diaminopyrazine-amide derivatives as NaV1.8 channel modulators and their preparation, pharmaceutical compositions and use in the treatment of pain. WO2008135830, 2008.
21. Ran, Y.; Jain, N.; Yalkowsky, S. H. Prediction of aqueous solubility of organic compounds by the general solubility equation (GSE) J. Chem. Inf. Comput. Sci. 2001, 41, 1208 - 1217
22. Hu, X.; Hu, Y.; Vogt, M.; Stumpfe, D.; Bajorath, J. MMP-Cliffs: systematic identification of activity cliffs on the basis of matched molecular pairs J. Chem. Inf. Model. 2012, 52, 1138 - 45
23. Fray, M. J.; Gillmore, A. T.; Glossop, M. S.; McManus, D. J.; Moses, I. B.; Praquin, C. F. B.; Reeves, K. A.; Thompson, L. R. Optimization of permanganate oxidation and Suzuki-Miyaura coupling steps in the synthesis of a Nav1.8 sodium channel modulator Org. Process Res. Dev. 2010, 14, 263 - 271